Despite the great efficacy of first- and second-generation EGFR-TKIs in patients with kinase-activating mutations in EGFR64,67, the EGFR T790M mutation in exon 2068 is associated with acquired resistance to these first- and second-generation EGFR-TKIs67,69 (e.g., approximately half of NSCLC patients acquire resistance to first-generation EGFR-TKIs69). Here, EGFR is linked to non-small cell lung carcinoma.